Oseltamivir dosing for influenza infection in premature neonates.
about
Innovative clinical trial design for pediatric therapeuticsOseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir.Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unitPharmacokinetic studies in infants using minimal-risk study designsOseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.Determination of appropriate dosing of influenza drugs in pediatric patients.The use of antiviral drugs for influenza: Guidance for practitioners, 2012/2013; Paediatric summaryApplications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak.Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Prematurity and the burden of influenza and respiratory syncytial virus disease.Oseltamivir for influenza infection in children: risks and benefits.Oseltamivir dosing in premature infants.The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.Oseltamivir treatment for influenza does not increase digestive intolerance in preterm infants.Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.L’utilisation d’antiviraux contre l’influenza : des conseils pour les praticiens en 2012–2013 – Sommaire relatif à la pédiatrie.Viral Respiratory Infections in the Neonatal Intensive Care Unit-A Review
P2860
Q24635308-FD792092-5989-4F59-9537-0178105DB28DQ30409023-B4AF68E3-E953-4C1A-98A1-7C9018C23634Q34389114-A3BDC6FA-2438-41FA-B49E-42CF07534E43Q34483638-4EB7A198-A0CB-4501-BE78-A927E7A2067EQ34743315-A1E1C4E9-34A3-4977-9653-D354F7CB9E85Q36086446-6BBB6DC2-2305-478F-887F-93A9B8E1B2BDQ36438116-E242031D-E8F4-484C-AD8E-51AFEF86C70EQ36584645-15F743BF-7114-45F0-A226-DFD1757B3624Q36630178-704D4C75-C51A-48AB-B521-ADCB989C13DDQ36922941-D2FFAA22-4077-4AC6-8BAE-E01EAFBB7405Q37259653-5D5EBBDC-D082-4482-BBCD-AFA60E72A842Q37828363-8EC09956-8C9B-448B-9590-B73798DFF887Q38051213-25F3C04F-EFAF-4B27-A6DE-3C4EF9999F09Q38084212-8BAF5B5D-6FF1-44D6-8150-2B506A82F6D4Q38637989-C5D99110-5D1E-4000-91D1-F1549559CF4EQ38652336-E9D2517A-0676-4935-AE35-EBF61A08E43FQ41890159-3B8494BB-9EA8-4437-B574-54F451653F16Q42216493-DE8D2D96-E8DC-46ED-8794-3F7C3DECC964Q42246526-9C69D818-0D6A-4F12-9275-6089BEEE101CQ43663687-BA9112CC-B823-41D4-9426-CF393C857E77Q46499031-43975D51-12CE-4DFA-B651-CAF56859F8DFQ58587564-48A67FDC-CF6A-40FA-923F-3D10A8E8F159
P2860
Oseltamivir dosing for influenza infection in premature neonates.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oseltamivir dosing for influenza infection in premature neonates.
@ast
Oseltamivir dosing for influenza infection in premature neonates.
@en
type
label
Oseltamivir dosing for influenza infection in premature neonates.
@ast
Oseltamivir dosing for influenza infection in premature neonates.
@en
prefLabel
Oseltamivir dosing for influenza infection in premature neonates.
@ast
Oseltamivir dosing for influenza infection in premature neonates.
@en
P2093
P2860
P356
P1476
Oseltamivir dosing for influenza infection in premature neonates.
@en
P2093
David W Kimberlin
Edward P Acosta
John Wimmer
National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group
Penelope Jester
Richard J Whitley
P2860
P304
P356
10.1086/654930
P407
P577
2010-08-01T00:00:00Z